Dr. Adviti Naik | Hamad Bin Khalifa University
Hamad Bin Khalifa University


Dr. Adviti Naik

Dr. Adviti Naik

Postdoctoral Researcher
Translational Cancer and Immunity Center
Qatar Biomedical Research Institute


Dr. Adviti Naik holds a Masters in Genetics and Molecular Cell Biology from the University of Sheffield, UK and was awarded a joint PhD in Systems Biology from the Eberhard Karls University of Tubingen, Germany and the University of Ljubljana, Slovenia. She received a prestigious Marie Curie Network European Union grant to conduct her PhD research in computational modeling of liver metabolism in relation to Non-alcoholic Fatty Liver Disease and hepatocellular carcinoma. After her PhD, Dr. Adviti Naik undertook a postdoctoral position at the Sultan Qaboos University (SQU), Oman, where she was involved in a clinical breast cancer study in collaboration with the Sultan Qaboos Hospital. As part of this study, Dr Naik dissected the downstream signaling of the placental growth factor (PlGF)/neuropilin (NRP-1) pathway and assessed the biomarker potential of the pathway for the diagnosis of breast cancer and prediction of chemoresistance.

Dr Naik was awarded the William Ferdinand Memorial Award and several scholarships for her educational excellence. In addition, she gained experience in the pharma-industry through an industrial placement at the Oncology department of AstraZeneca Pharmaceuticals, UK.

Dr Naik joined Dr. Julie Decock’s team in 2018 as a postdoctoral researcher and is involved in various projects exploring the role of cancer testis antigens in the oncogenesis and tumor progression of breast cancer.


Research Interests

Dr. Naik is interested in advancing the development of new treatment modalities for breast cancer subtypes with a poor prognosis that do not benefit from the currently available targeted therapeutics. She is in particular passionate about unravelling the mechanisms that drive the aggressiveness of triple negative breast cancer, and to identify novel biomarkers and/or targets that reflect the disease progression, immunogenicity, and chemo-sensitivity of triple negative breast cancer.

Selected Publications

  • Naik A, Al-Zeheimi N, Bakheit CS, Al Riyami M, Al Jarrah A, Al Moundhri MS, Al Habsi Z, Basheer M, Adham SA (2017).

    Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study. Sci Rep. 7(1):3301. doi: 10.1038/s41598-017-03280-0.

  • A. Naik, D. Rozman, A. Belič (2014).

    SteatoNet: the first integrated human metabolic model with multi-layered regulation to investigate liver-associated pathologies. PLoS Comput Biol 10(12):e1003993. doi: 10.1371/journal.pcbi.1003993

  • A. Naik, R. Košir, D. Rozman (2013).

    Genomic aspects of NAFLD. Genomics, 102 (2), 84-95.

  • A. Naik, A. Belič, U.M. Zanger, D. Rozman (2013).

    Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet. 4:2. doi: 10.3389/fgene.2013.00002.

  • A. Belič, J. Ačimovič, A. Naik, M. Goličnik (2013).

    Analysis of the steady-state relations and control-algorithm characterisation in a mathematical model of cholesterol biosynthesis. Simulation Modeling Practice and Theory, 33: 18-27.